MET and cancer: Finally, multivariate analysis for OS revealed that a strong c-MET IHC staining score of 3+ (hazard ratio [HR]: 2.05, 95% CI: 1.23–3.43; p = 0.006), initial brain metastasis (HR: 3.86, 95% CI: 1.52–9.82; p = 0.005), and treatment with supportive care without anti-cancer therapy (HR: 11.78, 95% CI: 3.40–40.86; p < 0.001) were associated with poor survival outcomes (Table 2).